Tezspire (tezepelumab ... The current therapies include Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab), which competes with ...

In the BOREAS and NOTUS trials, Dupixent cut the rate of exacerbations ... On the face of it, the Tezspire data suggest it could offer higher efficacy, although, a truer picture won’t emerge ...

As per Sanofi’s financials, Dupixent pulled in €10.7bn ($11.6bn) in global sales last year. Whilst Tezspire raked in $86m in ...

Also Read: Amgen/AstraZeneca’s Asthma Drug Tezspire Vs. Sanofi/Regeneron’s Blockbuster Dupixent – Analyst Gives His Pick WAYPOINT is a randomized, double-blind trial that evaluated the ...

TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo Positive high-level results from the ...

Dupixent's potential could be cut short by the approval of novel oral dermatitis drugs (AbbVie's Rinvoq) or injectable asthma therapies (Amgen/Astra's Tezspire), which could be more effective.

Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s ...

The trial demonstrated patients treated with TEZSPIRE ® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal ...

Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s TEZSPIRE ...